Like CML, relapsed Ph positive ALL patients exhibit similar mutations in BCR-ABL that impart TKI resistance, requiring a move to second and third generation BCR-ABL inhibitors. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.